McKesson falls as Q1 revenue misses estimates
** Shares of drug distributor McKesson Corp MCK.N fall 11.2% to $548.2
** Co late on Wednesday reported Q1 revenue below expectations due to soft demand for branded drugs, mainly AbbVie's ABBV.N arthritis drug Humira, and specialty medicines at its U.S. business
** U.S. pharmaceutical unit revenue came in at $71.7 billion, below analysts' expectations of $74.1 billion -LSEG data
** "Given that management did not reduce U.S. Pharma guidance, we are more sanguine that this is not necessarily a major profit headwind to the company," J.P.Morgan analyst Lisa Gill wrote in a note
** MCK raised 2025 adj EPS outlook to between $31.75 and $32.55 vs $31.25 to $32.05 per share previously
** "While we understand that investors may be disappointed by McKesson's Q1 given the high bar entering the quarter, we remain constructive on MCK's growth outlook," Gill added
** Including session moves, stock up ~19% YTD
Reporting by Mariam Sunny in Bengaluru
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
